|
|
|
|
| LEADER |
01802nam a2200373 u 4500 |
| 001 |
EB001897073 |
| 003 |
EBX01000000000000001060078 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200523 r ||| eng |
| 100 |
1 |
|
|a Cowling, Tara
|
| 245 |
0 |
0 |
|a Fluoroquinolones for the treatment of other respiratory tract infections
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Tara Cowling, Kelly Farrah
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2019, May 31, 2019
|
| 300 |
|
|
|a 1 PDF file (36 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Fluoroquinolones / adverse effects
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Respiratory Tract Infections / drug therapy
|
| 653 |
|
|
|a Fluoroquinolones / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Anti-Bacterial Agents / therapeutic use
|
| 653 |
|
|
|a Practice Guidelines as Topic
|
| 653 |
|
|
|a Anti-Bacterial Agents / economics
|
| 653 |
|
|
|a Fluoroquinolones / economics
|
| 700 |
1 |
|
|a Farrah, Kelly
|e [author]
|
| 700 |
1 |
|
|a Cowling, Tara
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK545102
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Fluoroquinolones (FQs) are a common class of antibiotic used for the treatment of infections, including those of the respiratory tract. However, the use of FQs has been controversial as certain types are associated with antibiotic resistance and adverse events
|